Marshall Fordyce - 15 Sep 2026 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Reporting relationship: PRESIDENT AND CEO, Director
Issuer ticker: VERA
Reported as of: 15 Sep 2026
Net transaction value: -$684,500
SEC form: 4
Accepted by SEC: 17 Sep 2026, 16:28:41 UTC
Prior SEC filing: 04 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Joseph R. Young, Attorney-in-Fact

Key filing fact

Marshall Fordyce filed Form 4 for Vera Therapeutics, Inc. (VERA) on 17 Sep 2026.

Key facts

This page summarizes Marshall Fordyce's Form 4 filing for Vera Therapeutics, Inc. (VERA).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Sep 2026, 16:28.

Change

Previous filing in this sequence was filed on 04 Sep 2026.
Current net transaction value: -$684,500.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001859453 Primary reporting owner

Fordyce Marshall

Relationship: PRESIDENT AND CEO, Director
Address: C/O VERA THERAPEUTICS, INC., 2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Signature: /s/ Joseph R. Young, Attorney-in-Fact
Signature date: 17 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VERA transaction

Class A Common Stock

Options Exercise

Transaction value
Shares: +18,500
Change %: +7.9%
Price: $2.90^*
Shares after: 253,744
Date: 15 Sep 2026
Ownership: Direct

VERA transaction

Class A Common Stock

Sale

Transaction value: $684,500
Shares: -18,500
Change %: -7.3%
Price: $37.00
Shares after: 235,244
Date: 15 Sep 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VERA transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -18,500
Change %: -3.6%
Price: $0.000000^*
Shares after: 488,801
Date: 15 Sep 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 18,500
Exercise price: $2.90
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

Footnote F2

1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter.